SCHEMBL2069971

SCHEMBL2069971

CCOC(=O)c1ccn(-c2ccc(C)cc2C)c1C(=O)OCC

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.47
TP53 P04637 3/20 0.47
ALDH1A1 P00352 3/20 0.41
KDM4E B2RXH2 3/20 0.41
TSHR P16473 2/20 0.41
GLA P06280 1/20 0.41
GAA P10253 1/20 0.41
HPGD P15428 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.40
PIM1 P11309 1/20 0.40
IRAK1 P51617 1/20 0.40
CAMK2B Q13554 1/20 0.40
CAMK2G Q13555 1/20 0.40
CAMK2D Q13557 1/20 0.40
PIM3 Q86V86 1/20 0.40
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
CA12 O43570 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2069863 0.83 TSHR (0.44) LMNAALDH1A1KDM4ETSHRGLA
SCHEMBL2069945 0.82 KDM4E (0.45) LMNATP53ALDH1A1KDM4ETSHR
SCHEMBL2069815 0.76 KDM4E (0.47) LMNAALDH1A1KDM4ETSHRHPGD
SCHEMBL2070675 0.75 GABRG2 (0.46) LMNATP53ALDH1A1TSHRSMN1; SMN2
SCHEMBL1107151 0.74 MEN1 (0.60) LMNAALDH1A1KDM4ETSHRHPGD
SCHEMBL29668381 0.74 MEN1 (0.60) LMNAALDH1A1KDM4ETSHRHPGD
SCHEMBL2071880 0.72 CYP11B2 (0.46) LMNATP53ALDH1A1KDM4ESMN1; SMN2
SCHEMBL4834369 0.71 MEN1 (0.60) LMNATP53ALDH1A1KDM4ETSHR
SCHEMBL31173650 0.70 TSHR (0.53) ALDH1A1KDM4ETSHRGLAGAA
SCHEMBL31454211 0.70 JMJD6 (0.48) TP53ALDH1A1KDM4ETSHRGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2522670-A1 Heterocyclic CRF receptor antagonists Takeda Pharmaceutical Company Limited (JP) 2012-11-14 EP disclosed
US-7897607-B2 Cyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-03-01 US disclosed
EP-1732541-A4 CYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL (JP) 2008-03-05 EP disclosed
US-20070179165-A1 Cyclic compounds GYORKOS ALBERT C 2007-08-02 US disclosed
EP-1732541-A2 CYCLIC COMPOUNDS Takeda Pharmaceutical Company Limited (JP) 2006-12-20 EP disclosed
WO-2005099688-A2 CYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-10-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070179165-A1 Cyclic compounds CRHR1, CRHR2, MC2R LMNA 3131/4885TP53 4425/4885ALDH1A1 786/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.